Adapted from previously published coverage.

These days, Jessica Yih spends a lot of time talking to women about testosterone. Interest is "coming from all directions," says the University of California, Irvine Health urologist. A major source: women who hope testosterone can boost the female libido. Only about a decade ago, women looking for libido treatments had few medical options — even though women of all ages struggle with low sexual desire.

Some non-hormonal treatments are now available, but the U.S. Food and Drug Administration has yet to approve a female testosterone product, despite years of research suggesting it can boost sexual function and desire among postmenopausal women. Female testosterone products are approved in countries including the United Kingdom and Australia.

Not many studies have looked at testosterone's effects on libido in premenopausal women, but preliminary data in that area are also promising, according to a 2026 research review in The Journal of Sexual Medicine that Yih coauthored. "I have seen it change people's lives," Yih says. The hormone seems to make the female brain more receptive to sexual stimuli; it also promotes physical effects that enhance sexual pleasure, such as increased blood flow to the genitals. Right now, American women interested in these potential benefits have to look for them off-label. But that may change. In September, the FDA held a public meeting on testosterone use among menopausal women, "with the goal of informing future research and potential drug development in this area," says Kaveeta Vasisht, the FDA's associate commissioner for women's health.

The hormone has a rocky regulatory past. In 2004, an FDA advisory panel unanimously voted against approving a testosterone patch for women, citing a lack of safety data. There are still outstanding questions on that front, Yih says—like how, if at all, long-term use affects risk of conditions such as breast cancer and heart disease. Then, in 2011, a pair of Phase III trials found that testosterone therapy didn't significantly outperform a placebo — a benchmark the FDA looks for when deciding whether to approve a new drug. That's not to say testosterone didn't work, says Tami Rowen, an ob-gyn at UC San Francisco. Rather, it seemed that hype about the hormone was so strong that study participants went in with sky-high expectations, leading even the placebo group to report benefits. The treatment was a "victim of its own success," Rowen says.

Interest hasn't let up, though. By one estimate, the U.S. female prescription rate for all uses rose from 0.4 out of every 1,000 women in 2018, to 1.8 out of every 1,000 women in 2026. That's an increase of nearly 400 percent. With so much buzz, the potential placebo effect remains "the biggest problem with testosterone right now," Rowen says.

Another outstanding question, Yih says, is whether using testosterone long-term increases the risk of breast cancer and heart disease.

Women seeking a libido boost do have non-hormonal options. In 2015, the FDA approved Addyi, the first treatment for low libido in premenopausal women. The drug seemingly raises levels of neurotransmitters that promote sexual desire while tamping down those that block it. A competitor, Vyleesi, hit shelves in 2019. Then, last year, regulators expanded Addyi's use to postmenopausal women younger than 65. An international group of experts, including Rowen, issued recommendations for treating low female libido in 2025 in Sexual Medicine Reviews. Psychological therapies and Addyi are backed by the strongest evidence, the group found.

Rowen currently has her eye on in-development products including Lybrido. The drug, which is slated to enter a Phase III clinical trial in Europe, aims to rev sex drive in the brain and enhance physical arousal. The demand for new treatments is there, Rowen says. "Women deserve better than placebo."

Comments 0

No comments yet. Start the conversation.

Leave a comment